SEC Comment Letter 0000000000-24-009094 to Nuvation Bio Inc. (NUVB, NUVB-WT) (CIK 0001811063) (NUVB)
Nuvation Bio Inc. (NUVB, NUVB-WT) (CIK 0001811063)
Date: Aug. 8, 2024 · CIK: 0001811063 · Accession: 0000000000-24-009094
AI Filing Summary & Sentiment
File numbers found in text: 333-281255
Letter
August 8, 2024 David Hung Chief Executive Officer Nuvation Bio Inc. 1500 Broadway, Suite 1401 New York, NY 10036 Re:Nuvation Bio Inc. Registration Statement on Form S-3 Filed August 5, 2024 File No. 333-281255 Dear David Hung: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Melissa H. Boyd, Esq.
Show Raw Text
August 8, 2024
David Hung
Chief Executive Officer
Nuvation Bio Inc.
1500 Broadway, Suite 1401
New York, NY 10036
Re:Nuvation Bio Inc.
Registration Statement on Form S-3
Filed August 5, 2024
File No. 333-281255
Dear David Hung:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Melissa H. Boyd, Esq.